J
Johanne I Weberpals
Researcher at Ottawa Hospital Research Institute
Publications - 68
Citations - 2894
Johanne I Weberpals is an academic researcher from Ottawa Hospital Research Institute. The author has contributed to research in topics: Rucaparib & Ovarian cancer. The author has an hindex of 20, co-authored 63 publications receiving 2022 citations. Previous affiliations of Johanne I Weberpals include Ottawa Hospital & University of Ottawa.
Papers
More filters
Journal ArticleDOI
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman,Amit M. Oza,Domenica Lorusso,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Andrew R Clamp,Giovanni Scambia,Alexandra Leary,Robert W Holloway,Margarita Amenedo Gancedo,Peter C.C. Fong,Jeffrey C. Goh,David M. O'Malley,Deborah K. Armstrong,Jesus Garcia-Donas,Elizabeth M. Swisher,Anne Floquet,Gottfried E. Konecny,Iain A. McNeish,Clare L. Scott,Terri Cameron,Lara Maloney,Jeff Isaacson,Sandra Goble,Caroline Grace,Thomas Harding,Mitch Raponi,James Sun,Kevin K. Lin,Heidi Giordano,Jonathan A. Ledermann,Martin Buck,A Dean,Michael Friedlander,J C Goh,Paul R. Harnett,G Kichenadasse,C L Scott,H Denys,Luc Dirix,Ignace Vergote,Laurie Elit,Prafull Ghatage,Amit M. Oza,Marie Plante,Diane Provencher,J I Weberpals,Stephen Welch,A Floquet,Laurence Gladieff,Florence Joly,A Leary,Alain Lortholary,Jean-Pierre Lotz,J. Medioni,Olivier Tredan,Benoit You,A El-Balat,C Hänle,P Krabisch,T Neunhöffer,M Pölcher,Pauline Wimberger,Amnon Amit,S Kovel,M Leviov,Tamar Safra,Ronnie Shapira-Frommer,Salomon M. Stemmer,Alessandra Bologna,N Colombo,Domenica Lorusso,Sandro Pignata,Roberto Sabbatini,G Scambia,Stefano Tamberi,Claudio Zamagni,P C Fong,A O'Donnell,M Amenedo Gancedo,A Casado Herraez,J Garcia-Donas,E M Guerra,A Oaknin,I Palacio,Iris L. Romero,A Sanchez,Susana Banerjee,A Clamp,Y Drew,Hani Gabra,D Jackson,Jonathan A. Ledermann,I A McNeish,Christine Parkinson,Melanie E Powell,C Aghajanian,D K Armstrong,Michael J. Birrer,Mary K. Buss,Setsuko K. Chambers,L-m Chen,Robert L. Coleman,R W Holloway,G E Konecny,L Ma,Mark A. Morgan,R T Morris,David G. Mutch,D M O'Malley,B M Slomovitz,E M Swisher,T Vanderkwaak,M Vulfovich +116 more
TL;DR: This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Journal ArticleDOI
EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer
Alexandria Haslehurst,Madhuri Koti,Moyez Dharsee,Paulo Nuin,Kenneth R. Evans,Joseph Geraci,Timothy Childs,Jian Chen,Jieran Li,Johanne I Weberpals,Scott Davey,Jeremy A. Squire,Paul C. Park,Harriet Feilotter +13 more
TL;DR: This work strongly suggests that genes associated with EMT may play a significant role in cisplatin resistance in ovarian cancer, therefore potentially leading to the development of predictive biomarkers of drug response or novel therapeutic strategies for overcoming drug resistance.
Journal ArticleDOI
Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma
Stephanie Lheureux,Marcus O. Butler,Blaise Clarke,Mihaela C. Cristea,Lainie P. Martin,Katia Tonkin,Gini F. Fleming,Anna V. Tinker,Hal W. Hirte,Daliah Tsoref,Helen Mackay,Neesha C. Dhani,Prafull Ghatage,Johanne I Weberpals,Stephen Welch,Nhu-An Pham,Vinicius Motta,Valentin Sotov,Lisa Wang,Katherine Karakasis,Smitha Udagani,Suzanne Kamel-Reid,Howard Streicher,Patricia Shaw,Amit M. Oza +24 more
TL;DR: Ipilimumab was tolerable in this population of women with metastatic cervical cancer but did not show significant single-agent activity, and immune changes were induced by anti–CTLA-4 therapy butdid not correlate with clinical activity.
Journal ArticleDOI
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Stephanie Lheureux,Mihaela C. Cristea,Jeff Bruce,Swati Garg,Michael Cabanero,Gina Mantia-Smaldone,Alexander B. Olawaiye,Susan Ellard,Johanne I Weberpals,Andrea E. Wahner Hendrickson,Gini F. Fleming,Stephen Welch,Neesha C. Dhani,Tracy Stockley,Prisni Rath,Katherine Karakasis,Gemma N Jones,Suzanne Jenkins,Jaime Rodriguez-Canales,Michael Tracy,Qian Tan,Valerie Bowering,Smitha Udagani,Lisa Wang,Charles A. Kunos,Eric Chen,Trevor J. Pugh,Amit M. Oza +27 more
TL;DR: In this paper, the Wee1 inhibitor combined with gemcitabine was evaluated in patients with high-grade serous ovarian cancer, a TP53-mutated tumour type with high replication stress.
Journal ArticleDOI
The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer
Johanne I Weberpals,Kyla Garbuio,Anna O'Brien,Katherine V. Clark-Knowles,Steve Doucette,Olga Antoniouk,Glenwood D. Goss,Jim Dimitroulakos +7 more
TL;DR: Low BRCA1 and ERCC1 expression correlate with improved survival in advanced OC and HDAC inhibition induces synergistic cytotoxicity with platinum in vitro, suggesting that this compound directly targets DNA repair.